

the peer-review panel and NTP staff prior to the meeting.

Persons wishing to make oral comments, including those who originally registered to present comments at the October 7–8, 2013 and those now interested in making comments, are asked to register online at <http://ntp.niehs.nih.gov/go/38853> by December 5, 2013. As noted in the previous **Federal Register** notice (78 FR 51733), oral public comments may be presented in person or by teleconference line and will adhere to the procedures stated in that notice. The lines will be open from 8:30 a.m. until approximately 5:00 p.m. EST on December 12 and from 8:30 a.m. EST until adjournment on December 13, and oral comments will be received only during the formal public comment periods indicated on the preliminary agenda.

Dated: November 6, 2013.

John R. Bucher,

Associate Director, National Toxicology Program.

[FR Doc. 2013–26937 Filed 11–8–13; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Diversity R03 Applications in Digestive Diseases and Nutrition.

Date: December 16, 2013.

Time: 12:00 p.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Thomas A. Tatham, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 760, 6707 Democracy Boulevard, Bethesda, MD 20892–5452, (301) 594–3993, tathamt@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: November 5, 2013.

David Clary,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013–26900 Filed 11–8–13; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Aging Amended; Notice of Meeting

Notice is hereby given of a change in the meeting of the National Institute on Aging Special Emphasis Panel, October 3, 2013, 1:00 p.m. to October 3, 2013, 3:00 p.m., DoubleTree by Hilton Hotel Bethesda, 8120 Wisconsin Avenue, Bethesda, MD, 20814 which was published in the **Federal Register** on September 10, 2013, 55265–55266 FR 175.

Meeting will be held November 20, 2013 from 12 p.m. to 3 p.m. at the National Institute on Aging, 7201 Wisconsin Avenue, Suite 2C212, Bethesda, MD 20892. The meeting is closed to the public.

Dated: November 4, 2013.

Melanie J. Gray,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013–26907 Filed 11–8–13; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Evaluation of Trichloroethylene for the Report on Carcinogens; Request for Nominations of Scientific Experts for Proposed Webinar

SUMMARY: The National Toxicology Program (NTP) Office of the Report on Carcinogens (ORoC) requests nominations of speakers for a proposed webinar to obtain information related to evaluating the potential association of exposure to trichloroethylene (TCE) and cancer.

DATES: The deadline for receipt of nominations of speakers is December 9, 2013.

ADDRESSES: Information can be submitted electronically on the ORoC TCE Web page (<http://ntp.niehs.nih.gov/go/37899>) or to lunn@niehs.nih.gov.

FOR FURTHER INFORMATION CONTACT: Dr. Ruth Lunn, Director, ORoC, Division of the NTP, NIEHS, P.O. Box 12233, MD K2–14, Research Triangle Park, NC 27709. Phone: (919) 316–4637, FAX: (301) 480–2970, email: lunn@niehs.nih.gov. Hand Delivery/Courier: NIEHS, Room 2138, 530 Davis Drive, Morrisville, NC 27560.

SUPPLEMENTARY INFORMATION:

Information on Proposed Webinar: TCE is a candidate substance under evaluation for the Report on Carcinogens (RoC) (<http://ntp.niehs.nih.gov/go/37899>). Several comprehensive reviews have identified non-Hodgkin's lymphoma and cancer of the liver and kidney as sites of concern in humans, and the RoC evaluation will be limited to these outcomes.

As part of the evaluation, the ORoC proposes to convene a webinar to obtain input on scientific issues related to evaluating human epidemiologic studies of exposure to TCE and cancer risk and use this input to help inform its cancer evaluation of TCE. The webinar will include a series of presentations by invited speakers that address the quality of the methods used in the epidemiology studies to assess exposure to TCE and cancer outcome (primarily lymphohematopoietic cancer) and information on TCE exposure in the studies. Speakers on exposure and cancer-outcome classification will be asked to (1) identify the methods used to assess exposure or outcome, (2) discuss the validity and reliability of the methods used to classify exposure (such as job title, job exposure matrix, biomonitoring, and expert assessment) or cancer outcome (such as mortality or incidence data), and (3) examine how misclassification of exposure (either qualitative or quantitative) or cancer outcome would affect interpretation of the study's findings. The speaker addressing TCE exposure will be asked to compare measured or estimated levels of exposure to TCE and its prevalence in the epidemiologic studies and to discuss how these data may explain potential heterogeneity of findings across studies and inform the assessment for a specific type of cancer.

It is envisioned that the webinar will include time for questions to speakers by webinar attendees and open discussion. Once plans are finalized, the list of speakers and logistical details for